相关实验视频

Updated: Jul 24, 2025

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

一个简单的语言概要的ritlecitinib治疗成人和青少年与白发性脱发

Brett King¹, Xingqi Zhang², Walter Gubelin Harcha³

¹Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA.

|July 5, 2023

概括

利特利西丁有效治疗成人和青少年的严重脱发症 (AA),促进头皮,眉毛和毛的显著头发再生. 在48周的时间里,这种治疗耐受性很好.

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
临床药理学临床药理学

背景情况:

脱发症 (AA) 是一种自身免疫性疾病,在这种疾病中,免疫系统错误地攻击毛囊,导致脱发.
利特利西替尼 (Ritlecitinib) 是一种已批准的口服药物,用于严重的AA,该药物向涉及脱发的关键途径.

研究的目的:

评估Ritlecitinib在治疗成人和青少年严重脱发区域的疗效和安全性.
为了评估与安慰剂相比,接受利西提尼布的参与者的头发再生和患者报告的结果.

主要方法:

在ALLEGRO 2b/3期临床试验中,参与者包括成人和青少年 (12岁以上) 随机选择接受ritelecitinib或安慰剂.
治疗持续时间为48周,一些参与者在24周内切换了安慰剂到利西提尼布.
疗效终点包括头皮头发的再生和患者报告的AA严重程度的改善.

主要成果:

与安慰剂相比,Ritelecitinib在24周内显示出较高的头皮头发再生.
在Ritlecitinib治疗的眉毛和眼上也观察到显著的头发再生.
持续改善的头发再生和患者报告的结果被记录到48周.

结论:

利特利西替尼 (Ritlecitinib) 是一种有效且耐受性很好的治疗方法,用于在48周内治疗严重的脱发症.
这项研究证实了ritlecitinib在解决免疫媒介脱发方面的治疗潜力.

关键词:

青少年青少年青少年脱发的区域有脱发的区域.脱发脱发脱发脱发脱发脱发脱发脱发脱发里特莱西提尼布 (ritlecitinib) 是一种药物.

更多相关视频

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...